Cochrane · systematic review · CD007803
Augmentation of cognitive and behavioural therapies (CBT) with d‐cycloserine for anxiety and related disorders
Ori, R, Amos, T, Bergman, H, et al. · Cochrane Database of Systematic Reviews · 2015 · Cochrane Library
Common Mental DisordersAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
14
current version
GRADE rated
13
No studies
1
Included studies
NR
No studies 1 · 7.1%Ungraded 0 · 0%Very low 5 · 35.7%Low 4 · 28.6%Moderate 4 · 28.6%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
DCS and cognitive and behavioural therapies compared to placebo and cognitive and behavioural therapies for anxiety disorders in adults
Population: Adults with anxiety disorders
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Treatment efficacy: treatment responders As assessed per study DCS and cognitive and behavioural therapies vs placebo and cognitive and behavioural therapies | RR 1.1 [0.89, 1.34] | 9 studies · 449 participants | Low Downgraded: risk of bias, inconsistency |
Treatment acceptability: withdrawals from treatment DCS and cognitive and behavioural therapies vs placebo and cognitive and behavioural therapies | RR 0.88 [0.61, 1.25] | 16 studies · 740 participants | Moderate Downgraded: indirectness |
In remission As assessed per study DCS and cognitive and behavioural therapies vs placebo and cognitive and behavioural therapies | RR 1.16 [0.79, 1.71] | 5 studies · 292 participants | Moderate Downgraded: risk of bias, imprecision, inconsistency, indirectness |
Condition‐specific anxiety symptoms As assessed by LSAS5 (scale from: 0 to 144, better indicated by a lower score. 55 to 65 points = moderate social anxiety disorder (Liebowitz 1987)) DCS and cognitive and behavioural therapies vs placebo and cognitive and behavioural therapies | no estimate extracted | 17 studies · 735 participants | Moderate Downgraded: risk of bias, imprecision, inconsistency, indirectness |
Co‐morbid symptoms of depression As assessed by BDI‐II7 (scale from: 0 to 63, better indicated by a lower score) DCS and cognitive and behavioural therapies vs placebo and cognitive and behavioural therapies | no estimate extracted | 5 studies · 178 participants | Moderate Downgraded: risk of bias, imprecision, inconsistency, indirectness |
Co‐morbid anxiety symptoms As assessed by BAI9 (scale from: 0 to 63, better indicated by a lower score. 8 to 15 points = mild anxiety, 16 to 25 points = moderate anxiety (Beck 1993)) DCS and cognitive and behavioural therapies vs placebo and cognitive and behavioural therapies | no estimate extracted | 3 studies · 122 participants | Low Downgraded: risk of bias, imprecision, inconsistency, indirectness |
Quality of life Assessed by LIS (scale from: 0 to 48, better indicated by a lower score) DCS and cognitive and behavioural therapies vs placebo and cognitive and behavioural therapies | no estimate extracted | 1 study · 56 participants | Very low Downgraded: risk of bias, imprecision, inconsistency, indirectness |
DCS and cognitive and behavioural therapies compared to placebo and cognitive and behavioural therapies for anxiety disorders in children and adolescents
Population: Children and adolescents with anxiety disorders
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Treatment efficacy: treatment responders As assessed per study DCS and cognitive and behavioural therapies vs placebo and cognitive and behavioural therapies | RR 1.01 [0.78, 1.31] | 4 studies · 121 participants | Low Downgraded: imprecision |
Treatment acceptability: withdrawals from treatment DCS and cognitive and behavioural therapies vs placebo and cognitive and behavioural therapies | RR 0.9 [0.17, 4.69] | 4 studies · 131 participants | Very low Downgraded: imprecision, indirectness |
In remission As assessed per study DCS and cognitive and behavioural therapies vs placebo and cognitive and behavioural therapies | RR 1.19 [0.66, 2.16] | 2 studies · 44 participants | Low Downgraded: imprecision |
Condition‐specific anxiety symptoms As assessed by Y‐BOCS3 (scale from 0 to 40, better indicated by a lower score) DCS and cognitive and behavioural therapies vs placebo and cognitive and behavioural therapies | no estimate extracted | 4 studies · 131 participants | Very low Downgraded: imprecision, inconsistency |
Co‐morbid symptoms of depression As assessed by CDI5 (scale from 0 to 54, better indicated by a lower score) DCS and cognitive and behavioural therapies vs placebo and cognitive and behavioural therapies | no estimate extracted | 3 studies · 114 participants | Very low Downgraded: imprecision, inconsistency |
Co‐morbid anxiety symptoms As assessed by each study DCS and cognitive and behavioural therapies vs placebo and cognitive and behavioural therapies | no estimate extracted | 3 studies · 104 participants | Very low Downgraded: risk of bias, imprecision, inconsistency |
Quality of life DCS and cognitive and behavioural therapies vs placebo and cognitive and behavioural therapies | no estimate extracted | NR | No studies |